Drug Trial Radar · NCT07833696
Characteristics and Management of Patients With Severe Chronic Spontaneous and/or Inducible Urticaria Refractory to Optimized Omalizumab Treatment: A French Multicenter Observational Study.
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
73
Planned (sponsor's estimate)
Start
Jan 1, 2020
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Centre Hospitalier Universitaire de BesanconAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 22, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is sponsored by the University Hospital of Besancon under the coordination of Dr. Julie Castagna from the Department of Dermatology and Allergology. Approximately ten percent of patients with severe chronic urticaria remain refractory to standard or optimized biologic therapy, and this observational multicenter retrospective project aims to thoroughly evaluate these challenging cases. By analyzing a target population of seventy adult participants across French hospitals, the research focuses on identifying specific clinical and biological traits, outlining risk factors associated with non-response to high-dose treatment regimens, and documenting the alternative therapeutic strategies that follow treatment failure. Data collection is structured retrospectively to cover the period from January 2020 through the end of December 2026, leveraging existing medical records without imposing any additional clinical visits or physical procedures on participants, aside from sending an informational mailer to ensure transparency regarding data utilization. Eligibility requires documented resistance to optimized omalizumab defined by a validated Urticaria Control Test score below six or less than fifty percent clinical improvement as judged by the investigator, alongside mandatory affiliation with the French social security scheme and a lack of objection from the participant regarding the secondary use of their personal health information. Strictly enforced exclusion conditions eliminate cases where omalizumab was initiated for alternative diagnoses, halted due to adverse side effects, or administered to vulnerable groups such as pregnant individuals, minors, or those under legal protection frameworks. To maintain absolute data integrity and regulatory compliance, individual participant data will not be shared publicly or externally because the documentation contains confidential and fully anonymized clinical details designed strictly to safeguard patient privacy throughout the research lifecycle.
Conditions
- Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Interventions
drug effectDrug
description of the characteristics and management of patients with severe chronic spontaneous and/or inducible urticaria experiencing failure of treatment with optimized omalizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients showing known risk factors for omalizumab resistance.Time frame: Data collection between 2020 and the end of 2026
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CHU Minjoz BESANCON
Besançon, Franche-comté, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.